Targeted therapies for lung cancer patients with oncogenic driver molecular alterations
Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …
understanding of disease biology and the identification of oncogenic driver alterations has …
Advances in systemic therapy for non-small cell lung cancer
M Miller, N Hanna - Bmj, 2021 - bmj.com
Lung cancer remains a leading cause of cancer related mortality worldwide. Despite
numerous advances in treatments over the past decade, non-small cell lung cancer …
numerous advances in treatments over the past decade, non-small cell lung cancer …
Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09)
JH Cho, SH Lim, HJ An, KH Kim, KU Park… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Approximately 10% of patients with epidermal growth factor receptor (EGFR)
mutation–positive non–small-cell lung cancer (NSCLC) harbor uncommon mutations. Here …
mutation–positive non–small-cell lung cancer (NSCLC) harbor uncommon mutations. Here …
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
PURPOSE Standard first-line therapy for EGFR-mutant advanced non–small-cell lung
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Purpose: Osimertinib was initially approved for T790M-positive non–small cell lung cancer
(NSCLC) and, more recently, for first-line treatment of EGFR-mutant NSCLC. However …
(NSCLC) and, more recently, for first-line treatment of EGFR-mutant NSCLC. However …
[HTML][HTML] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang, V Hirsh… - Annals of …, 2017 - Elsevier
ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
[HTML][HTML] Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
The traditional approach to the treatment of patients with advanced-stage non-small-cell
lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been the …
lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been the …
[HTML][HTML] Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 …
VA Papadimitrakopoulou, TS Mok, JY Han, MJ Ahn… - Annals of …, 2020 - Elsevier
Background In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth
factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression …
factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression …
[HTML][HTML] Overview of current systemic management of EGFR-mutant NSCLC
Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is
the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 …
the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 …
[HTML][HTML] Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer …
ACZ Gelatti, A Drilon, FC Santini - Lung cancer, 2019 - Elsevier
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …